Safety Assessment of the Food Enzyme D-Allulose 3-Epimerase from Genetically Modified Escherichia coli

A new EFSA opinion clears the enzyme route to allulose

Formulators now have one less regulatory headache. EFSA’s scientific panel evaluated d-allulose 3-epimerase produced by a genetically modified Escherichia coli strain and closed the case with no safety concerns under the intended use. The opinion, published under DOI 10.2903/j.efsa.2025.9666, covers the enzyme as a food processing aid for carbohydrate processing. For buyers who source enzymes for EU-market products, that is a significant green light.

Why this enzyme matters

Allulose is a rare sugar with about 70% of sucrose’s sweetness and almost no metabolizable energy. You cannot extract it cheaply from nature. Commercial production relies on enzymatic conversion. The enzyme performs an epimerization reaction at carbon 3 of D-fructose, turning it into D-allulose. A single stereocenter flips. That small change transforms the molecule’s physical and nutritional behavior.

The assessed process uses the enzyme in immobilized form. This design matters for manufacturers. Immobilized enzymes remain in the reactor, survive multiple production cycles, and do not carry over into the final syrup. That simplifies downstream purification. It also lowers enzyme cost per kilogram of allulose produced.

EFSA’s ruling applies specifically to the food enzyme. You still need to validate your own supply chain and verify the final sweetener meets food-grade specifications. But the enzyme itself no longer stands as a barrier.

What the panel evaluated

The EFSA panel reviewed the enzyme’s source, its production strain, and the intended food process. The production strain is a genetically modified E. coli. The panel assessed the enzyme preparation, the immobilized immobilization system, and the substrate it acts on. That substrate is D-fructose. The product is d-allulose, classified here as a specialty carbohydrate.

The scope was precise. The safety conclusion covers the enzyme preparation as specified in the application and its use under the stated conditions. That means the panel did not issue a blanket approval for every allulose enzyme on the market. It approved this enzyme, in this form, for this reaction.

Key findings

The table below summarizes the core points of the safety assessment.

Assessment point	Finding
Source organism	Genetically modified Escherichia coli
Enzyme activity	D-allulose 3-epimerase, epimerizing D-fructose at C-3
Physical form	Immobilized preparation
Intended application	Carbohydrate processing to produce D-allulose
Safety conclusion	No concerns under intended conditions of use

The key data point sits in the enzyme’s name. The 3-epimerase flips the hydroxyl group at carbon 3. That positional specificity means the reaction produces D-allulose without generating a mixture of other sugar isomers. Clean conversion translates to simpler downstream purification and better yield.

The panel also considered the immobilized form in its risk assessment. Immobilization reduces the potential for the enzyme protein to appear in the final food. That is a decisive factor for a safety evaluation.

What it means for formulators and buyers

First, check your supplier’s documentation. If you buy enzyme preparations for allulose production destined for the EU, you need evidence that the specific preparation falls under this positive opinion. Not every epimerase product is automatically covered. Confirm the strain, the production process, and the enzyme identity match the approved specification.

Second, the immobilized format changes your process economics. You can reuse the catalyst. That lowers enzyme spend per batch and reduces downtime for enzyme replacement. Plants designed around soluble enzymes may need to adapt reactor configuration, but the long-term cost advantage is real.

Third, this opinion separates the enzyme from the sweetener. The EFSA conclusion does not make allulose itself legal in every EU food category. You must still align the final ingredient with relevant food additive or novel food rules. Treat the enzyme approval as one component in a larger compliance framework.

Questions formulators ask

Is the enzyme made using GMO technology? Yes. The assessed preparation comes from a genetically modified E. coli strain. EFSA evaluated that specific strain and found no safety concerns under the intended use.

Does this approval cover all allulose enzymes? No. The opinion is specific to this enzyme, its production strain, and its immobilization method. A different strain or a soluble enzyme preparation would require its own assessment.

Can the EFSA opinion support approvals in other markets? It supports the EU regulatory path. Other jurisdictions run independent review processes. Many will accept EFSA data as part of a submission, but none treat it as automatic approval.

A clearer path forward

The 2025 EFSA opinion removes a major obstacle for EU-compliant allulose production. Buyers now have a recognized benchmark for enzyme safety. Suppliers have a clear specification to match. The remaining work is on the formulator side: verify your source, confirm your process conditions, and keep the documentation ready for audit. The enzyme was the hard part. Now it is solved.